Business Case

Indication prioritization for an early-stage oncology asset

Our client, an early clinical-stage company, was looking to develop and commercialize their first asset, which was a cancer vaccine with the potential to address multiple cancer tumor types. Keeping in mind the client’s limited resources situation, LSC was able to combine internal and external evidence, and leverage a prioritization framework to develop recommendations on tumor types to pursue in collaboration with the client team. Results of the project led to initiation of clinical trials with recommended tumor types and ultimately, the client organization was acquired by a top biopharma company.